CA2259123C - Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth - Google Patents

Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth Download PDF

Info

Publication number
CA2259123C
CA2259123C CA002259123A CA2259123A CA2259123C CA 2259123 C CA2259123 C CA 2259123C CA 002259123 A CA002259123 A CA 002259123A CA 2259123 A CA2259123 A CA 2259123A CA 2259123 C CA2259123 C CA 2259123C
Authority
CA
Canada
Prior art keywords
seq
oligonucleotide
nucleic acid
gene
ribonucleotide reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002259123A
Other languages
English (en)
French (fr)
Other versions
CA2259123A1 (en
Inventor
Jim A. Wright
Aiping H. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptose Biosciences Inc
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of CA2259123A1 publication Critical patent/CA2259123A1/en
Application granted granted Critical
Publication of CA2259123C publication Critical patent/CA2259123C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002259123A 1996-07-01 1997-06-30 Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth Expired - Fee Related CA2259123C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2115296P 1996-07-01 1996-07-01
US60/021,152 1996-07-01
PCT/CA1997/000454 WO1998000532A2 (en) 1996-07-01 1997-06-30 Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth

Publications (2)

Publication Number Publication Date
CA2259123A1 CA2259123A1 (en) 1998-01-08
CA2259123C true CA2259123C (en) 2003-10-21

Family

ID=21802643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002259123A Expired - Fee Related CA2259123C (en) 1996-07-01 1997-06-30 Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth

Country Status (6)

Country Link
US (2) US7223849B1 (enExample)
EP (1) EP0954574A2 (enExample)
JP (1) JP2000513230A (enExample)
AU (1) AU3249897A (enExample)
CA (1) CA2259123C (enExample)
WO (1) WO1998000532A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000513230A (ja) 1996-07-01 2000-10-10 エイ． ライト，ジム ハウスキーピング遺伝子の非翻訳領域由来のオリゴヌクレオチドおよび細胞増殖を調節するためのその使用方法
US6593305B1 (en) 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
WO1998041231A1 (en) * 1997-03-19 1998-09-24 Genesense Technologies, Inc. Suppression of malignancy utilizing ribonucleotide reductase r1
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
EP1597365B1 (en) 2003-02-10 2013-10-09 Lorus Therapeutics Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
AU2005203822A1 (en) * 2004-01-12 2005-07-21 Lorus Therapeutics Inc. Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3854823T2 (de) 1987-05-01 1996-05-23 Stratagene Inc Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
CA1327869C (en) * 1989-02-17 1994-03-15 Yvan Guindon Ribonucleotide reductase inhibitors
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5288846A (en) 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
WO1993002556A1 (en) 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2127450C (en) 1992-01-07 2007-04-17 Samuel Wadsworth Transgenic animal models for alzheimer's disease
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
EP0672178A4 (en) * 1992-02-19 1996-03-20 Baylor College Medicine CELL GROWTH MODULATION WITH OLIGONUCLEOTIDS.
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
AU6490894A (en) * 1993-03-23 1994-10-11 Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators
WO1994023049A2 (en) 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
ATE216709T1 (de) * 1995-02-07 2002-05-15 Kyowa Hakko Kogyo Kk Monoklonäler antikörper gegen die r2-untereinheit von ribonukleotid-reduktase
JP2000513230A (ja) 1996-07-01 2000-10-10 エイ． ライト，ジム ハウスキーピング遺伝子の非翻訳領域由来のオリゴヌクレオチドおよび細胞増殖を調節するためのその使用方法
ATE309345T1 (de) * 1996-08-02 2005-11-15 Genesense Technologies Inc Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase

Also Published As

Publication number Publication date
WO1998000532A2 (en) 1998-01-08
CA2259123A1 (en) 1998-01-08
WO1998000532A3 (en) 1998-03-05
EP0954574A2 (en) 1999-11-10
US20070032442A1 (en) 2007-02-08
AU3249897A (en) 1998-01-21
JP2000513230A (ja) 2000-10-10
US7223849B1 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
CA2259123C (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
EP0917569B1 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
EP0748383B1 (en) Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences
EP1153128B1 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
JPH1052264A (ja) Ｎ‐ｒａｓ発現阻害剤およびその方法
Benedict et al. Triple ribozyme-mediated down-regulation of the retinoblastoma gene.
US6593305B1 (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
EP1090146B1 (en) Uses of dna-pk
US6399298B1 (en) Ku70—related methods
EP0971731B1 (en) Suppression of malignancy utilizing ribonucleotide reductase r1
AU9732101A (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
KR100986465B1 (ko) Ｏｉｐ５ 유전자의 신규한 용도
Byrne et al. Antisense Methods in Cell Culture
HK1024640B (en) Suppression of malignancy utilizing ribonucleotide reductase r1
HK1036483B (en) Uses of dna-pk

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130703